false
OasisLMS
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
Life Cycle Considerations in Hypoparathyroidism
Recorded Q&A Session with the Faculty
Recorded Q&A Session with the Faculty
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In a live Q&A session, Dr. Bart L. Clark and Dr. Vafa Tabatabi, both experts in endocrinology, addressed various aspects of managing hypoparathyroidism. Key topics included appropriate calcium supplements, with a preference for calcium citrate due to better absorption, and the management of hyperphosphatemia through dietary adjustments and calcium supplements during meals. The panel discussed the necessity of magnesium supplementation based on individual patient needs and the importance of maintaining 25-hydroxyvitamin D levels to support potential extra-skeletal benefits.<br /><br />Dr. Clark highlighted that hypoparathyroidism can occasionally resolve spontaneously, particularly in cases of autoimmune origins. They also discussed the need for genetic testing in younger patients or those with syndromic features or family history. The panel emphasized the value of parathyroid hormone analogs in managing phosphorus levels and discussed the potential future availability and insurance challenges of new treatments. <br /><br />The experts addressed dietary considerations, involving dieticians primarily for managing hyperphosphatemia rather than routine care. They also highlighted the importance of monitoring bone density, particularly in postmenopausal women, due to the risk of rapid bone loss. The session concluded with a call for continuous learning and sharing of rare findings through case studies.
Keywords
hypoparathyroidism
calcium citrate
hyperphosphatemia
magnesium supplementation
25-hydroxyvitamin D
genetic testing
parathyroid hormone analogs
bone density
×